-
公开(公告)号:US07517996B2
公开(公告)日:2009-04-14
申请号:US11346426
申请日:2006-02-03
申请人: Takashi Yamamoto , Akira Chiba , Koichi Fujita , Yuka Kataba , Koji Ohsumi , Sayaka Asari , Naoyuki Fukuchi , Misato Noguchi , Itsuya Tanabe , Chiori Ijichi , Naoko Oomuta , Yuko Iida , Satoshi Iwayama
发明人: Takashi Yamamoto , Akira Chiba , Koichi Fujita , Yuka Kataba , Koji Ohsumi , Sayaka Asari , Naoyuki Fukuchi , Misato Noguchi , Itsuya Tanabe , Chiori Ijichi , Naoko Oomuta , Yuko Iida , Satoshi Iwayama
IPC分类号: C07D261/04 , A01N43/80
CPC分类号: A61K31/4245 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/433
摘要: Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.
摘要翻译: 由式I表示的唑类化合物:其中环A是异恶唑等,R 1是取代或未取代的芳基等,R 2是氢原子等,R 3是取代或未取代的烷基等, 和其药学上可接受的盐抑制溶血磷脂酸(LPA)的生理活性,并且可用于预防或治疗其中抑制LPA的生理活性用于预防或治疗其的疾病,例如涉及 LPA受体。
-
公开(公告)号:US20130041000A1
公开(公告)日:2013-02-14
申请号:US13585011
申请日:2012-08-14
申请人: Takashi YAMAMOTO , Akira Chiba , Koichi Fujita , Yuka Kataba , Koji Ohsumi , Sayaka Asari , Naoyuki Fukuchi , Misato Noguchi , Itsuya Tanabe , Chiori Ijichi , Naoko Oomuta , Yuko Iida , Satoshi Iwayama
发明人: Takashi YAMAMOTO , Akira Chiba , Koichi Fujita , Yuka Kataba , Koji Ohsumi , Sayaka Asari , Naoyuki Fukuchi , Misato Noguchi , Itsuya Tanabe , Chiori Ijichi , Naoko Oomuta , Yuko Iida , Satoshi Iwayama
IPC分类号: A61K31/42 , A61P1/16 , C07D261/14
CPC分类号: A61K31/4245 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/433
摘要: Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.
-
公开(公告)号:US20090170911A1
公开(公告)日:2009-07-02
申请号:US12389711
申请日:2009-02-20
申请人: Takashi YAMAMOTO , Akira Chiba , Koichi Fujita , Yuka Kataba , Koji Ohsumi , Sayaka Asari , Naoyuki Fukuchi , Misato Noguchi , Itsuya Tanabe , Chiori Ijichi , Naoko Oomuta , Yuko Iida , Satoshi Iwayama
发明人: Takashi YAMAMOTO , Akira Chiba , Koichi Fujita , Yuka Kataba , Koji Ohsumi , Sayaka Asari , Naoyuki Fukuchi , Misato Noguchi , Itsuya Tanabe , Chiori Ijichi , Naoko Oomuta , Yuko Iida , Satoshi Iwayama
IPC分类号: A61K31/4192 , C07D261/14 , A61K31/42 , C07D275/02 , A61K31/425 , C07D271/00 , A61K31/4245 , C07D285/06 , C07D285/10
CPC分类号: A61K31/4245 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/433
摘要: Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.
摘要翻译: 由式I表示的唑类化合物:其中环A是异恶唑等,R 1是取代或未取代的芳基等,R 2是氢原子等,R 3是取代或未取代的烷基等, 和其药学上可接受的盐抑制溶血磷脂酸(LPA)的生理活性,并且可用于预防或治疗其中抑制LPA的生理活性用于预防或治疗其的疾病,例如涉及 LPA受体。
-
-